YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.05 CNY | +3.43% |
|
-1.71% | -34.26% |
| 27/05 | Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug | MT |
| 20/05 | Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 | CI |
ETFs positioned on Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 114 M€ | +7.37% | - | |
| 0.00% | 32 M€ | +4.91% | - |
Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Companyâs main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
31/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.05
CNY
Average target price
17.8
CNY
Spread / Average Target
+47.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.26% | 136.69Cr | |
| +24.53% | 4.51TCr | |
| +30.99% | 2.34TCr | |
| +24.13% | 1.61TCr | |
| +21.15% | 1.46TCr | |
| +68.67% | 1.4TCr | |
| -0.05% | 678.76Cr | |
| -13.29% | 637.59Cr | |
| -8.87% | 572.55Cr | |
| +13.53% | 563.98Cr |
- Stock Market
- Equities
- 002675 Stock
- ETFs Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
